Cybin Inc

ASE:CYBN 4:00:00 PM EDT

9.18

+0.62 (+7.24%)

4:40:48 PM EDT: $9.01 -0.17 (-1.85%)

Cybin Inc Stock, ASE:CYBN

100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9

Phone: +1.908.764.8385

Number of Employees:

http://www.cybin.com

Description

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.